News & Updates
September 2023
Saros Therapeutics awarded Phase 2 SBIR from the National Cancer Institute
Saros Therapeutics Receives $2 Million Direct-to-Phase 2 SBIR Grant from the National Cancer Institute to Advance STING Agonist Program Chicago, Illinois – September 21, 2023 – Saros Therapeutics, a new biotech company specializing in oncology research and development, announced today that it has been… [Read More]
May 2023
Saros Therapeutics accepted to pitch at BIO’s selective Startup Stadium in Boston on June 6th between 11am and 1pm
During the 2024 BIO International Convention, 47 select finalists from 13 different countries each shared a quick pitch showcasing new technologies and therapeutic solutions to a panel of investor judges, followed by live feedback… [Read More]
April 2023
Moon Lab presenting key data from Saros’ STING program at 2023 annual ASCO meeting in Chicago
Activating the innate immune pathway of stimulator of interferon genes (STING) can elicit potent anti-tumor immunity via the production of type-I interferons (IFN-I). However, cyclic-dinucleotide (CDN) STING agonists have undesirable pharmacological properties. Most CDNs in clinical development are… [Read More]
October 2022
Frankel Award at the University of Michigan provides translational support for studies designed to validate mechanism of action in Saros’ STING program
The Frankel Innovation Initiative is a $20 million fund supporting the research and development of life-saving therapies and innovative new technologies at Michigan Medicine, with the ultimate goal of improving healthcare and saving lives… [Read More]
Get in Touch with Us.
Have questions or want to learn more about our innovative treatments? Reach out to our team—We welcome your collaboration to deliver improved cancer immunotherapy.